

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

RPMI-8226

RRID:CVCL_0014

Type: Cell Line

Proper Citation

RRID:CVCL_0014

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0014

Proper Citation: RRID:CVCL_0014

Description: Cell line RPMI-8226 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:1373872](#), [PMID:1720489](#), [PMID:2041050](#), [PMID:2140233](#), [PMID:2537114](#), [PMID:2563664](#), [PMID:2875788](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:3893568](#), [PMID:4177524](#), [PMID:4366935](#), [PMID:5243066](#), [PMID:5260617](#), [PMID:6042436](#), [PMID:6350451](#), [PMID:8943038](#), [PMID:9290701](#), [PMID:9331090](#), [PMID:9510473](#), [PMID:10087940](#), [PMID:10557056](#), [PMID:10583232](#), [PMID:10700174](#), [PMID:10936422](#), [PMID:11001907](#), [PMID:11154231](#), [PMID:11157491](#), [PMID:11515052](#), [PMID:12068308](#), [PMID:14555701](#), [PMID:15215163](#), [PMID:15748285](#), [PMID:16956823](#), [PMID:16957166](#), [PMID:17088437](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18277095](#), [PMID:18605421](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21173094](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23074853](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:29718670](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31465861](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine., Characteristics: Produces IgG lambda (PubMed=6042436; ATCC=CCL-155)., Population: African American., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human

Protein Atlas, Cell Atlas panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: RPMI-8226

Synonyms: RPMI 8226, RPMI.8226, RPMI8226, RPMI no. 8226, RPMI no 8226, RPMI #8226, 8226, RPMI 8226/S, RPMI-8226S, RPMI8226/S, 8226/S, Roswell Park Memorial Institute 8226, GM02132, GM2132, GM 2132, GM02132C, Simpson

Cross References: BTO:BTO_0000726, CLO:CLO_0008873, CLO:CLO_0031845, EFO:EFO_0002322, MCCL:MCC:0000406, CLDB:cl4182, CLDB:cl4183, CLDB:cl4184, CLDB:cl5252, AddexBio:C0003002/62, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ArrayExpress:E-TABM-937, ATCC:CCL-155, ATCC:CRM-CCL-155, BCRC:60384, BioGRID_ORCS_Cell_line:1003, BioSample:SAMN03471458, BioSample:SAMN03472934, BioSample:SAMN03473581, BioSample:SAMN10988318, cancercellines:CVCL_0014, CCRID:1101HUM-PUMC000083, CCRID:3101HUMTCHu234, Cell_Model_Passport:SIDM00087, CGH-DB:9162-4, ChEMBL-Cells:ChEMBL3307732, ChEMBL-Targets:ChEMBL614882, CLS:300431, Coriell:GM02132, Cosmic:720773, Cosmic:724856, Cosmic:742952, Cosmic:759915, Cosmic:760397, Cosmic:875867, Cosmic:886084, Cosmic:888018, Cosmic:897452, Cosmic:905964, Cosmic:919145, Cosmic:974250, Cosmic:991554, Cosmic:999791, Cosmic:1044255, Cosmic:1092628, Cosmic:1139509, Cosmic:1139639, Cosmic:1175858, Cosmic:1305340, Cosmic:1312326, Cosmic:1762461, Cosmic:1998470, Cosmic:2081405, Cosmic:2159574, Cosmic:2367260, Cosmic:2391801, Cosmic-CLP:905964, DepMap:ACH-000817, DSMZ:ACC-402, DSMZCellDive:ACC-402, ECACC:87012702, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, ENCODE:ENCBS457ZNO, ENCODE:ENCBS604KZU, GDSC:905964, GEO:GSM2135, GEO:GSM50198, GEO:GSM50261, GEO:GSM143340, GEO:GSM290304, GEO:GSM562819, GEO:GSM621590, GEO:GSM743461, GEO:GSM750813, GEO:GSM799349, GEO:GSM799412, GEO:GSM887548, GEO:GSM888631, GEO:GSM1153419, GEO:GSM1181289, GEO:GSM1181334, GEO:GSM1199922, GEO:GSM1199923, GEO:GSM1199924, GEO:GSM1199925, GEO:GSM1199926, GEO:GSM1199927, GEO:GSM1374855, GEO:GSM1666389, GEO:GSM1670389, GEO:GSM2124680, GEO:GSM7701441, GEO:GSM7701457, IARC_TP53:360, IARC_TP53:27232, IGRhCellID:RPMI8226, IZSLER:BS TCL 92, JCRB:IFO50013, JCRB:JCRB0034, KCLB:10155, LiGeA:CCLE_817, LINCS_LDP:LCL-2049, Lonza:61, NCBI_Iran:C210, NCI-DTP:RPMI-8226, PharmacODB:RPMI8226_1327_2019, PRIDE:PXD001276, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD013859, PRIDE:PXD030239, PRIDE:PXD030304, Progenetix:CVCL_0014, PubChem_Cell_line:CVCL_0014, RCB:RCB3010, SKY/M-FISH/CGH:2743, TKG:TKG 0243, Wikidata:Q54951245

ID: CVCL_0014

Record Creation Time: 20220427T221507+0000

Ratings and Alerts

No rating or validation information has been found for RPMI-8226.

No alerts have been found for RPMI-8226.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 771 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wan YH, et al. (2026) Monoclonal neutralizing antibodies elicited by infection with Kaposi sarcoma-associated herpesvirus reveal critical sites of vulnerability on gH/gL. PLoS pathogens, 22(1), e1013772.

Ghaemi B, et al. (2026) Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. Theranostics, 16(6), 2748.

Alsina M, et al. (2026) Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer immunology research, 14(4), 528.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. iScience, 29(5), 115669.

Tang H, et al. (2026) Aryl Aldehyde-Anchored Small Molecules Recruit FBXO22 for Targeted Degradation of NSD2. Journal of medicinal chemistry, 69(13), 15317.

Wang J, et al. (2026) Clostridium butyricum alleviates multiple myeloma by remodeling the bone marrow microenvironment and inhibiting PI3K/AKT pathway through the gut???bone axis. Gut microbes, 18(1), 2609455.

Shah UA, et al. (2026) A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model. Cancer discovery, 16(4), 697.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. Journal of molecular medicine (Berlin, Germany), 104(1), 45.

Tang K, et al. (2026) Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(21), e18975.

Takeda S, et al. (2026) A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. *Cancer research*, 86(8), 2024.

Gu H, et al. (2026) FAP^{hi} Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(18), e06239.

Wang L, et al. (2025) Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8⁺ T-Cell-Mediated Immunity against Multiple Myeloma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(42), e10888.

Yin Z, et al. (2025) Cinobufagin overcomes bortezomib resistance in multiple myeloma strains by targeting SEC62/TRPM4-mediated NECO. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 147, 157171.

Murphy CS, et al. (2025) Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. *Molecular oncology*, 19(6), 1687.

Shen N, et al. (2025) HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma. *Cell reports*, 44(5), 115720.

Yao R, et al. (2025) Identification of a new micropeptide altKLF4 derived from KLF4 that influences myeloma chemotherapeutic sensitivity. *Cellular signalling*, 131, 111767.

Xu MX, et al. (2025) A novel synthesised STAT3 inhibitor exerts potent anti-tumour activity by inducing lysosome-dependent cell death. *British journal of pharmacology*, 182(17), 4041.

Nikolic I, et al. (2025) Enhancing anti-tumor immunity of natural killer cells through targeting IL-15R signaling. *Cancer cell*.

Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. *Cancer research*, 85(13), 2448.